BURP7 Antibody

What is BP7 and how was it first identified?

BP7 is a seven-amino acid sequence (GGCDGAA) peptide isolated from the bursa of Fabricius in birds. It was identified through a methodical isolation process using RP-HPLC coupled to MALDI-TOF-MS and MS/MS analysis, where it was separated in a peak at 17.09 min during chromatography. Subsequent amino acid sequence analysis through MS/MS confirmed its unique heptapeptide structure. The peptide appears to be conserved across species, showing homology to proteins in both Gallus gallus and Mus musculus, suggesting evolutionary conservation of its functional domains .

How does the structure of BP7 relate to its immunomodulatory function?

The structural analysis of BP7 reveals it is likely a proteolytic degradation fragment of larger intact proteins, including interferon-induced helicase C domain-containing protein 1 (IFIH1) and immunoglobulin heavy chain variable region (IGHV) in Gallus gallus. IFIH1 functions as a pattern recognition receptor that activates innate immune responses upon binding with damage-associated molecular patterns, while IGHV is associated with Tfh17 cells and antigen-driven affinity maturation. This structural homology provides insights into how BP7 might interact with immune system components to enhance antibody production and modulate B cell development pathways .

What experimental models are suitable for studying BP7's immunomodulatory effects?

Multiple experimental models have proven effective for studying BP7's immunomodulatory functions:

• Hybridoma cell lines: Particularly useful for assessing BP7's effects on monoclonal antibody production. Experiments showed BP7 enhanced antibody production by 45.91%, 52.1%, and 27.55% at concentrations of 0.01, 0.1, and 1 μg/mL respectively, without significantly affecting cell proliferation .

• WEHI-231 immature B cell model: This mouse peripheral B cell line serves as an established immature B cell model for investigating BP7's effects on B cell development, particularly surface IgM expression and related signaling pathways .

• In vivo mouse immunization model: BALB/c female mice immunized with an AIV antigen plus BP7 demonstrated enhanced antibody responses and cell-mediated immune reactions, making this a valuable model for studying adjuvant properties .

• Chicken immunization models: Demonstrate BP7's potential as an immune-enhancing agent for vaccines, particularly for avian influenza virus (AIV) vaccines .

How does BP7 influence antibody production mechanisms in research settings?

BP7 exhibits significant enhancement of antibody production through multiple mechanisms. In hybridoma cells, BP7 treatment increased monoclonal antibody production by up to 52.1% at optimal concentrations (0.1 μg/mL) without affecting cell proliferation, suggesting direct modulation of antibody secretion machinery rather than simple proliferative effects. At the molecular level, BP7 regulates numerous genes involved in B cell activation and antibody production pathways. Gene microarray analysis of BP7-treated WEHI-231 cells revealed differential expression of genes involved in MHC class I and II biosynthetic processes, B cell activation, and B cell-mediated immunity. Additionally, BP7 stimulates AMPK-ULK1 phosphorylation and regulates Bcl-2 protein expression, which are critical for B cell survival and function during antibody production .

What methodological approaches should researchers employ to study BP7's effects on immature B cells?

Researchers investigating BP7's effects on immature B cells should consider a multi-faceted methodological approach:

• Gene expression analysis: Implement microarray or RNA-seq to identify differentially expressed genes. The study identified 2465 differentially regulated genes in BP7-treated WEHI-231 cells, providing substantial mechanistic insights .

• Signaling pathway analysis: Examine key signaling pathways affected by BP7 treatment. The research revealed 13 significantly enriched pathways, with ubiquitin-mediated proteolysis being particularly prominent .

• Protein expression and modification studies: Western blot analysis to assess changes in protein expression and post-translational modifications, particularly focusing on AMPK and ULK1 phosphorylation and Bcl-2 expression .

• Autophagy assessment: Monitor autophagosome formation using fluorescence microscopy and LC3 protein expression to evaluate autophagy induction, as BP7 stimulates autophagy in immature B cells .

• Surface marker analysis: Flow cytometry to measure changes in surface markers, particularly surface IgM (sIgM) expression, which was significantly increased in BP7-treated cells .

What are the challenges in translating BP7 research from avian to mammalian immunological systems?

Translating BP7 research from avian to mammalian systems presents several methodological challenges that researchers should address:

• Evolutionary conservation assessment: While BP7 shows sequence homology to proteins in both birds and mice, functional conservation may vary. Researchers should conduct comparative studies to verify mechanistic conservation across species.

• Receptor identification disparities: The specific receptors and binding partners for BP7 may differ between avian and mammalian systems, necessitating binding studies in each target species.

• Immune system architectural differences: The bursa of Fabricius is unique to birds, while mammals rely on bone marrow for B cell development. This fundamental difference requires careful experimental design when studying BP7's effects in mammalian models.

• Dosage and pharmacokinetic variations: Optimal concentrations for biological effects may differ between species (0.1 μg/mL was optimal in hybridoma cells), requiring dose-response studies in each experimental system .

• Adjuvant properties verification: While BP7 enhanced immune responses to AIV antigens in both mouse and chicken models, the magnitude and quality of these responses may differ across species, requiring comparative immunization studies .

How does BP7 modulate gene expression profiles in immature B cells?

BP7 exerts profound effects on gene expression profiles in immature B cells through multiple regulatory mechanisms. Microarray analysis of BP7-treated WEHI-231 cells identified 2465 differentially expressed genes compared to control cells. Of the significantly enriched GO terms with p values within TOP30, 73.33% belonged to biological processes and 13.33% to molecular functions. The modulated genes participate in crucial immune-related processes including:

• Lymphocyte regulation: Negative regulation of T cell and lymphocyte proliferation, and T helper 2 cell differentiation.

• Antigen processing: Genes involved in antigen processing and presentation, MHC class I and II biosynthetic processes.

• B cell functionality: B cell activation and B cell-mediated immunity.

• Cytokine activity: Cytokine activity and secretion pathways.

These expression changes collectively contribute to BP7's immunomodulatory effects. Additionally, BP7 activates 13 significantly enriched signaling pathways, with ubiquitin-mediated proteolysis emerging as particularly important. This pathway has been implicated in MHCII complexes, B cell responses, and B cell receptor signaling .

What role does autophagy play in BP7-mediated immune responses?

Autophagy plays a critical role in BP7-mediated immune responses, particularly in B cell development and function. Research demonstrates that BP7 significantly influences autophagy in immature B cells through multiple mechanisms:

• Gene regulation: BP7 modulates the expression of numerous genes involved in the autophagy pathway and autophagy-related biological processes.

• Autophagosome formation: BP7 treatment increases intracellular autophagosome formation in WEHI-231 cells.

• LC3 protein expression: BP7 stimulates the expression of LC3 protein, a key marker of autophagy.

• AMPK-ULK1 pathway activation: BP7 promotes AMPK and ULK1 phosphorylation, a critical interaction required for ULK1-mediated autophagy.

• Bcl-2 regulation: BP7 induces BCL-2 expression in WEHI-231 cells. Bcl-2 family members function as dual regulators of apoptosis and autophagy.

This autophagy modulation is particularly significant because autophagy is involved in numerous immune-related processes, including B and T cell development, antigen presentation by B cells, and the survival of memory lymphocytes and antibody-producing plasma cells. The exact mechanism by which BP7-induced autophagy contributes to immature B cell development and differentiation requires further investigation .

How do current AI-driven approaches compare with BP7 research for antibody development?

Modern AI-driven approaches like RFdiffusion represent a complementary but distinct path to antibody development compared to BP7 research:

While BP7 research focuses on understanding and enhancing natural antibody production mechanisms through a peptide isolated from the bursa of Fabricius, AI approaches like RFdiffusion create entirely new antibody designs computationally. RFdiffusion has been trained to build antibody loops—the intricate, flexible regions responsible for antibody binding—producing antibody blueprints unlike any seen during training that can bind user-specified targets. This approach has been validated through the design of antibodies against disease-relevant targets including influenza hemagglutinin and Clostridium difficile toxin .

These approaches could potentially be integrated, using BP7's biological enhancement mechanisms to optimize the production of AI-designed antibody structures, combining the strengths of both biological and computational methodologies.

What protocols are recommended for optimal BP7 isolation and purification?

The isolation and purification of BP7 from bursal tissue requires a precise multi-step protocol:

• Sample preparation: Fresh bursal tissue should be homogenized and extracted using ultrasonic sample preparation techniques to maximize yield while preserving peptide integrity.

• Initial fractionation: Apply reversed-phase high-performance liquid chromatography (RP-HPLC) for initial separation. The BP7 peptide elutes at approximately 17.09 minutes under standardized conditions .

• Mass spectrometry analysis: Subject isolated fractions to MALDI-TOF-MS analysis to identify peaks corresponding to the expected molecular weight of the heptapeptide.

• Sequence confirmation: Perform MS/MS analysis to determine and confirm the amino acid sequence (GGCDGAA) of the isolated peptide .

• Purity assessment: Evaluate peptide purity using analytical HPLC and mass spectrometry, targeting >95% purity for experimental applications.

• Synthetic alternative: For consistency in research applications, consider solid-phase peptide synthesis of BP7 based on the confirmed sequence, followed by HPLC purification and mass spectrometry validation.

• Storage optimization: Store purified BP7 in lyophilized form at -80°C or in solution (sterile PBS, pH 7.4) in single-use aliquots at -20°C to prevent freeze-thaw degradation.

This isolation protocol has been validated through functional assays, demonstrating that the isolated BP7 enhances monoclonal antibody production in hybridoma cells and stimulates immune responses in experimental models .

How should researchers design experiments to evaluate BP7's adjuvant potential in vaccine development?

Designing rigorous experiments to evaluate BP7's adjuvant potential requires a comprehensive approach:

• Animal model selection:

  • For preliminary studies: Use BALB/c female mice as demonstrated in previous research .

  • For target-specific validation: Select species relevant to the vaccine target (e.g., chickens for avian vaccines).

• Study design components:

  • Include positive control groups (established adjuvants like alum)

  • Include negative control groups (antigen alone without adjuvant)

  • Test multiple BP7 concentrations (ranging from 0.01-1 μg/mL based on in vitro data)

  • Plan appropriate time points for sample collection (7, 14, 21, and 28 days post-immunization)

• Immunization protocol:

  • Primary immunization with antigen + BP7

  • Boost immunization at day 14 or 21

  • Standardize injection routes (subcutaneous, intramuscular, or intraperitoneal)

• Comprehensive assessment metrics:

  • Antibody response: Measure antigen-specific antibody titers using ELISA

  • Antibody isotyping: Evaluate IgG1, IgG2a, IgG2b to assess Th1/Th2 bias

  • Cell-mediated immunity: Analyze T cell responses through cytokine profiling (IFN-γ, IL-4, IL-2)

  • Memory response: Challenge studies to assess protection

  • Safety parameters: Monitor for local and systemic adverse reactions

• Mechanistic investigations:

  • Dendritic cell activation and maturation assessment

  • Lymph node germinal center formation evaluation

  • Transcriptomic analysis of immune response genes

The experimental approach should be tailored to the specific vaccine candidate and target disease, with careful consideration of dose-dependent effects, as previous research showed varying efficacy at different concentrations (45.91%, 52.1%, and 27.55% enhancement at 0.01, 0.1, and 1 μg/mL respectively) .

What are the recommended methodologies for studying BP7's effects on B cell development pathways?

To comprehensively study BP7's effects on B cell development pathways, researchers should implement the following methodological approaches:

• Cell model selection:

  • Primary B cells at different developmental stages

  • WEHI-231 cell line as an established immature B cell model

  • Ex vivo bursal cells from avian sources

  • Bone marrow-derived B cell precursors from mammals

• Transcriptomic analysis:

  • RNA-sequencing or microarray analysis to identify differentially expressed genes

  • RT-qPCR validation of key developmental markers

  • Time-course experiments to capture dynamic expression changes

• Protein expression and signaling studies:

  • Western blot analysis of key B cell development proteins

  • Phosphorylation status of signaling molecules (particularly AMPK-ULK1 pathway)

  • Co-immunoprecipitation to identify protein-protein interactions

• Flow cytometry applications:

  • Surface marker analysis (e.g., sIgM, which was significantly upregulated in BP7-treated cells)

  • Intracellular signaling using phospho-specific antibodies

  • Cell cycle analysis and apoptosis assessment

• Functional assays:

  • B cell receptor (BCR) signaling assays

  • Antibody production measurement

  • Antigen presentation capacity

• Autophagy assessment:

  • LC3 conversion (LC3-I to LC3-II) by Western blot

  • Autophagosome formation using fluorescence microscopy

  • Autophagic flux measurement using lysosomal inhibitors

• Pathway inhibition studies:

  • Use specific inhibitors of the 13 identified signaling pathways

  • CRISPR/Cas9 knockout of key pathway components

  • siRNA knockdown of target genes

This multi-faceted approach will provide comprehensive insights into how BP7 influences B cell development at the molecular and cellular levels, building on the established finding that BP7 regulates 2465 differentially expressed genes and activates 13 signaling pathways in immature B cells .

What are the major limitations in current BP7 research and how might they be addressed?

Current BP7 research faces several significant limitations that require methodological solutions:

• Receptor identification uncertainty: The specific receptor(s) through which BP7 exerts its effects remain unidentified.

  • Solution: Implement receptor capture technologies, photoaffinity labeling with BP7 analogs, and genetic screening approaches to identify binding partners.

• Sequence optimization questions: Whether the natural GGCDGAA sequence represents the optimal configuration for immunomodulatory effects is unknown.

  • Solution: Conduct alanine scanning mutagenesis and systematic structure-activity relationship studies to identify critical residues and potentially enhance activity.

• Limited structural information: The three-dimensional structure of BP7 alone and in complex with potential binding partners remains uncharacterized.

  • Solution: Employ NMR spectroscopy, X-ray crystallography, and molecular dynamics simulations to elucidate structural features critical for function.

• Incomplete signaling pathway understanding: While 13 pathways have been identified, their relative contributions and interdependencies remain unclear.

  • Solution: Use pathway-specific inhibitors and genetic approaches to systematically dissect the contribution of each pathway to BP7's effects.

• Translation challenges between species: Differences between avian and mammalian immune systems complicate translational research.

  • Solution: Develop comparative immunology approaches that systematically evaluate BP7 effects across species with detailed molecular characterization.

• Limited long-term studies: Current research focuses predominantly on short-term effects without addressing long-term immunological memory.

  • Solution: Design longitudinal studies to assess the durability of BP7-enhanced immune responses and memory formation .

How do rabbit monoclonal antibodies compare with BP7-enhanced antibody approaches?

Rabbit monoclonal antibodies and BP7-enhanced antibody approaches represent different strategies in antibody research, each with distinct characteristics and applications:

Rabbit monoclonal antibodies have demonstrated outstanding performance in diagnostic applications, with 10 rabbit mAbs being used to detect tumor-associated antigens and one for detecting Helicobacter pylori infections. Additionally, rabbit mAb-derived therapeutics like sevacizumab and APX005M are in clinical trials. Their typical affinity range is 20-200 pM (median 66 pM), with some exhibiting affinities near 1 pM .

In contrast, BP7-enhanced approaches focus on boosting antibody production through immunomodulatory effects rather than generating specific antibody clones. BP7 has been shown to enhance monoclonal antibody production in hybridoma cells by up to 52.1% at optimal concentrations .

These approaches could potentially be complementary, using BP7's enhancement mechanisms to improve the production efficiency of high-quality rabbit monoclonal antibodies, combining the advantages of both systems.

What are the potential synergies between AI-driven antibody design and BP7-mediated immune enhancement?

The integration of AI-driven antibody design (like RFdiffusion) with BP7-mediated immune enhancement presents exciting research opportunities with potential synergistic effects:

• Optimized production of designed antibodies: BP7's demonstrated ability to enhance antibody production by up to 52.1% in hybridoma cells could potentially improve the yield of AI-designed antibodies when incorporated into production systems .

• Complementary design approaches: While RFdiffusion excels at designing antibody loops and binding regions against specific targets, BP7 enhances natural antibody production mechanisms. Combining these approaches could result in both precisely targeted and efficiently produced antibodies .

• Enhanced therapeutic efficacy: BP7's immunomodulatory effects extend beyond simply increasing antibody production to include broader immune response enhancement. This could potentially augment the therapeutic efficacy of AI-designed antibodies by recruiting additional immune mechanisms .

• Streamlined developmental pipeline:

  • AI design phase: Use RFdiffusion to create human-like antibodies against specific targets

  • Optimization phase: Incorporate BP7 in production systems to enhance yield

  • Validation phase: Test combined approach in relevant disease models

• Research methodology advancement: Developing protocols that integrate these approaches would require innovative experimental designs, potentially advancing both fields simultaneously.

• Potential applications:

  • Rapid response to emerging pathogens (using AI design speed combined with BP7's production enhancement)

  • Cancer immunotherapy (combining precisely targeted antibodies with enhanced immune activation)

  • Autoimmune disease treatment (where both specificity and modulation of immune responses are critical)

This integrated approach represents a promising frontier in antibody research, leveraging the computational power of AI design with the biological enhancement mechanisms of BP7 .